Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 600-616

  Bubalo, Joseph ^a   Carpenter, Paul A ^b   Majhail, Navneet ^c   Perales, Miguel Angel ^d,e   Marks, David I ^f   Shaughnessy, Paul ^g   Pidala, Joseph ^h   Leather, Helen L ⁱ   Wingard, John ⁱ   Savani, Bipin N ^j  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^g TEXAS TRANSPLANT INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF FLORIDA HEALTH   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Dosing; Hematopoietic cell transplantation; Obesity; Preparative regimens

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; PENTOSTATIN; THIOTEPA; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY MASS; BODY SURFACE; BODY WEIGHT; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHEMOTHERAPY; CONDITIONING CHEMOTHERAPY; DRUG DISPOSITION; DRUG DOSE REGIMEN; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAXIMUM TOLERATED DOSE; NONHUMAN; OBESITY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW; BONE MARROW TRANSPLANTATION; COMPLICATION; DOSE CALCULATION; DRUG ADMINISTRATION; HEMATOLOGIC DISEASES; PATHOLOGY;

ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ETOPOSIDE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MYELOABLATIVE AGONISTS; OBESITY; TRANSPLANTATION CONDITIONING;

EID: 84897958610     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.01.019     Document Type: Article

References (67)

1. Pai M.P. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012, 32:856-868.
2. Ogden CL, Carroll MD. Prevalence of obesity among children and adolescents: United States, trends 1963-1965 through 2007-2008. CDC/NCHS. June 2010: 5. Available at: :. Accessed: 3 Oct2013. http://www.cdc.gov/nchs/data/hestat/obesity_child_07_08/obesity_child_07_08.htm.
3. Ogden CL, Carroll MD, Kit BK, etal. Prevalence of obesity in the United States. CDC/NCHS 2009-2010. NCHS Data Brief 2012:1-8. Available at: Accessed: 3 Oct2013. http://www.cdc.gov/nchs/data/databriefs/db82.pdf.
4. Weiss B.M., Vogl D.T., Berger N.A., et al. Trimming the fat: obesity and hematopoietic cell transplantation. Bone Marrow Transplant 2013, 48:1152-1160.
5. Barlow S.E., Expert Committee Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120:S164-S192.
6. Green B., Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol 2004, 58:119-133.
7. O'Donnell P.H., Artz A.S., Undevia S.D., et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome. Leuk Lymph 2010, 51:2240-2249.
8. Perkins J.B., Kim J., Anasetti C., et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1099-1107.
9. Russell J.A., Kangarloo S.B., Williamson T., et al. Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biol Blood Marrow Transplant 2013, 19:1381-1386.
10. Griggs J.J., Mangu P.B., Anderson H., et al. Appropriate chemotherapy dosing for obese adults with cancer: American Society of Clinical Oncology Clinical Practice Guidelines. JClin Oncol 2012, 30:1553-1561.
11. Jaime-Perez J.C., Colunga-Pedraza P.R., Gutierrez-Gurrola B., et al. Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant. Blood Cells Mol Dis 2013, 51:61-65.
12. Vogl D.T., Wang T., Perez W.S., et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011, 17:1765-1774.
13. Kearns G.L., Abdel-Rahman S.M., Alander S.W., et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. NEngl J Med 2003, 349:1157-1167.
14. Bartelink I.H., Rademaker C.M., Schobben A.F., et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokin 2006, 45:1077-1097.
15. Liu H., Zhai X., Song Z., et al. Busulfan plus fludarabine as a myeloablative regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. JHematol Oncol 2013, 6:1-9.
16. Goldberg M.A., Antin J.H., Guinan E.C., et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986, 68:1114-1118.
17. Peters W.P., Eder J.P., Henner W.D., et al. High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. JClin Oncol 1986, 4:646-654.
18. Phillips G.L., Fay J.W., Herzig G.P., et al. Intensive 1,3-Bis(2-chlorethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer 1983, 52:1792-1802.
19. Glottzbecker B., Duncan C., Alyea E., et al. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 2012, 18:989-1006.
20. Deol A., Ratanatharathorn V., Uberti J.P. Pathophysiology, prevention, and treatment of acute-graft-vs-host disease. Transplant Res Risk Manage 2011, 3:31-44.
21. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
22. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation. 40 Years On. Hepatology 2010, 51:1450-1460.
23. Coghlin-Dickson T.M., Kusnierz-glaz C.R., Blume K., et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999, 5:299-305.
24. Navarro W.H., Agovi M.A., Logan B.R., et al. Obesity does not preclude safe and effective myeloablative hematopoietic transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant 2010, 16:1442-1450.
25. Nikolousis E., Nagra S., Paneesha S., et al. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematologic malignancies. Ann Hematol 2010, 89:1141-1145.
26. Fleming D.R., Rayens M.K., Garrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 1997, 102:265-268.
27. Sriharsha L., Lipton J.H., Pond G., et al. Examining the safety and efficacy of a chemotherapy dosing method in allogeneic stem cell transplant patients of extreme body size. JOncol Pharm Pract 2009, 15:201-210.
28. Costa L.J., Micalleff I.N., Inwards D.J., et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol 2008, 143:268-273.
29. Deeg H.J., Seidel K., Bruemmer B., et al. Impact of patient weight on non-relapse mortality after marrow transplant. Bone Marrow Transplant 1995, 15:461-468.
30. Hadjibabaie M., Tabeefar H., Alimoghaddam K., et al. The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical Transplant 2012, 26:149-155.
31. Navarro W.H. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003, 31:961-966.
32. Tarella C., Caracciolo D., Gavarotti P., et al. Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 2000, 26:1185-1191.
33. Sucak G.T., Suyani E., Baysal N.A., et al. The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol 2012, 95:95-101.
34. Barker C.C., Agovi M.A., Logan B., et al. Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant 2011, 17:737-744.
35. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
36. Przepiorka D., Madden T., Ippoliti C., et al. Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 1995, 37:155-160.
37. Van Besien K., Stock W., Rich E., et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:913-921.
38. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
39. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
40. Browning B., Thormann K., Donaldson A., et al. Busulfan dosing in children with BMI >85% undergoing HSCT: a new optimal strategy. Biol Blood Marrow Transplantation 2011, 17:1383-1388.
41. Copelan E.A., Penza S.L., Pohlman B., et al. Autotransplantation following busulfan, etoposide, and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 25:1243-1248.
42. Gibbs J.P., Gooley T., Corneau B., et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999, 93:4436-4440.
43. Kebriaei P., Madden T., Kazerooni R., et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011, 17:412-420.
44. Russel J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
45. Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987, 70:1382-1388.
46. Zhang H., Graiser M., Hutcherson D.A., et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1287-1294.
47. Langebrake C., Bernhardt F., Baehr M., et al. Drug dosing and monitoring in obese patients undergoing stem cell transplantation. Int J Clin Pharm 2011, 33:918-924.
48. Schiltmeyer B., Klingebiel T., Schwab M., et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003, 52:209-216.
49. Nguyen L., Leger F., Lennon S., et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006, 57:191-198.
50. Booth B.P., Rahman A., Dagher R., et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. JClin Pharm 2007, 47:101-111.
51. Colby C., Koziol S., McAfee S.L., et al. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant 2002, 26:467-472.
52. De Jonge M.E., Mathot R.A., van Dam S.M., et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa, and carboplatin. Cancer Chemother Pharmacol 2002, 50:251-255.
53. Huitema A.D., Spaander M., Mathot R.A., et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin. Ann Oncol 2002, 13:374-384.
54. Petros W.F., Broadwater G., Berry D., et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002, 8:698-705.
55. Takvorian T., Parker L.M., Hochberg F.H., et al. Autologous bone-marrow transplantation: host effects of high-dose BCNU. JClin Oncol 1983, 1:610-620.
56. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. NEngl J Med 1998, 338:962-968.
57. Meloni G., Proia A., Capria S., et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 2001, 28:365-367.
58. Mullins G.M., Anderson P.N., Santos G.W. High dose cyclophosphamide therapy in solid tumors. Cancer 1975, 36:1950-1958.
59. Tolar J., Deeg H.J., Arai S., et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 2012, 18:1007-1011.
60. Robien K., Schubert M.M., Bruemmer B., et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. JClin Oncol 2004, 22:1268-1275.
61. Kroger N., Zabelina T., Sonnenberg S., et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000, 26:711-716.
62. Blijlevens N., Schwenkglenks M., Bacon P., et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. JClin Oncol 2008, 26:1519-1525.
63. Gertz M.A., Ansell S.M., Dingli D., et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clinic Proc 2008, 83:1131-1135.
64. Grazziutti M.L., Dong L., Micelli M.H., et al. Oral mucositis in myelomapatients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors, and a severity predictive model. Bone Marrow Transplant 2006, 38:501-506.
65. Kassar M., Medoff E., Seropian S., et al. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007, 47:115-119.
66. Lazarus H.M., Herzig R.H., Graham-Pole J., et al. Intensive melphalan chemotherapy and cryopreserved autologous marrow transplantation for the treatment of refractory cancer. JClin Oncol 1983, 1:359-367.
67. Nath C.E., Shaw P.J., Montgomery K., et al. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 2004, 59:314-324.